Back Hepatitis C

Hepatitis C

AASLD 2016: AbbVie Pangenotypic Combination Cures 98% or More Across HCV Genotypes

AbbVie’s combination of glecaprevir and pibrentasvir cured at least 98% of people with hepatitis C in 3 large clinical trials covering 5 out of 6 genotypes of the virus, and it is likely to receive marketing approval in the United States and European Union as the first ribavirin-free pangenotypic direct-acting antiviral combination next year, according to a report at the AASLD Liver Meeting last week in Boston.

alt

AASLD 2016: AbbVie Pangenotypic Combination Cures Hard-to-Treat People with HCV Genotype 3

AbbVie’s pangenotypic combination of glecaprevir and pibrentasvir cured almost all of the hardest-to-treat genotype 3 hepatitis C patients -- those with cirrhosis or previous treatment experience -- in a Phase 2 trial, and looks suitable for use as an 8-week regimen for HCV genotypes 2, 4,5 and 6, according to results of studies presented at the AASLD Liver Meeting last week in Boston.

alt

IDWeek 2016: New Triple DAA Combo Cures 96%-99% of People with Genotype 1-6 Hepatitis C

A new 3-drug regimen of sofosbuvir, velpatasvir, and voxilaprevir, taken without ribavirin for 8 weeks, produced sustained virological response in 96% of previously untreated patients with all hepatitis C virus (HCV) genotypes, while a 12-week course cured 99% of treatment-experienced patients, researchers reported at the recent IDWeek meeting in New Orleans. Response rates dropped off, however, when treatment was shortened to 6 weeks.

alt

AASLD 2016: Grazoprevir/ Elbasvir + Sofosbuvir Highly Effective for Hard-to-Treat Genotype 3 HCV Patients

A triple regimen of grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hepatitis C virus (HCV) genotype 3 and liver cirrhosis, matching rates seen in easier-to-treat patient groups, according to results from the C-ISLE study presented this week at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston.

alt

HIV Glasgow: Generic Hepatitis C Drugs Purchased Online Produce High Cure Rates

Use of generic versions of direct-acting antivirals for hepatitis C resulted in very high cure rates for people who obtained the products through 3 buyers’ clubs, indicating that the generic products are effective, according to a set of poster presentations at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) last week. People who purchased generic drugs were cured at a cost of around US$700-$900 in Southeast Asia and Eastern Europe, Andrew Hill of St. Stephen’s AIDS Trust reported.

alt

AASLD 2016: Real-World Responses to HCV Treatment Among U.S. Veterans Match Best Clinical Trial Results

Direct-acting antiviral treatment is curing people of hepatitis C in real-world clinical practice at similar rates to those seen in clinical trials, and there do not seem to be major differences between drug regimens, according to results of a large population study presented this weekend at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston.

alt

Over 1 Million People Have Been Treated with New Hepatitis Drugs, But Cost Remains a Barrier

More than 1 million people have now received hepatitis C treatment using the new highly effective and well-tolerated direct-acting antiviral agents despite their high cost, according to a report released this week by the World Health Organization. The Global Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers is available online.

alt

AASLD 2016: Liver Cancer Risk Reduced After Hepatitis C Treatment, But Vigilance Needed

People who are cured of hepatitis C after a course of direct-acting antiviral treatment do not have a higher risk of developing hepatocellular carcinoma (HCC) -- and probably have a reduced risk -- according to studies from Italy and Canada presented at American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

New Triple Combo Cures Most DAA-Experienced and Hard-to-Treat Hepatitis C Patients Without Ribavirin

An investigational 3-drug coformulation from Gilead Sciences produced sustained virological response (SVR) in 95% to 97% of hard-to-treat hepatitis C patients in the Phase 3 POLARIS trials, including people who were previously treated with direct-acting antivirals and those with hepatitis C virus (HCV) genotype 3 and compensated cirrhosis, according to a recent company announcement. Gilead plans to request Food and Drug Administration approval of the new combination by the end of the year.

alt